Cubist Pharmaceuticals (Nasdaq:CBST) hit a new 52-week high Monday as it is currently trading at $49.94, above its previous 52-week high of $49.86 with 49,619 shares traded as of 9:50 a.m. ET. Average volume has been 760,600 shares over the past 30 days.
Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model. NEW YORK ( TheStreet) -- Cubist Pharmaceuticals (Nasdaq: CBST) hit a new 52-week high Monday as it is currently trading at $49.94, above its previous 52-week high of $49.86 with 49,619 shares traded as of 9:50 a.m. ET. Average volume has been 760,600 shares over the past 30 days. Cubist has a market cap of $3.17 billion and is part of the health care sector and drugs industry. Shares are up 15.6% year to date as of the close of trading on Friday. Cubist Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of pharmaceutical products for various medical needs in the acute care environment in the United States. The company has a P/E ratio of 27.9, above the S&P 500 P/E ratio of 17.7.
EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass.
TheStreet Ratings rates Cubist as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, reasonable valuation levels, expanding profit margins and increase in stock price during the past year. We feel these strengths outweigh the fact that the company has had sub par growth in net income. You can view the full Cubist Ratings Report. See all 52-week high stocks or get investment ideas from our investment research center. Exclusive Offer: Jim Cramer's 'go-to' small/mid-cap guru Bryan Ashenberg only buys stocks he thinks could return 50-100% See his top picks for 14-days FREE.